Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma

Shankar Siva; Rodney J. Ellis; Lee Ponsky; Bin S. Teh; Anand Mahadevan; Alexander Muacevic; Michael Staehler; Hiroshi Onishi; Peter Wersall; Takuma Nomiya; Simon S. Lo

doi:10.2217/fon.16.2

Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma

Shankar Siva, Rodney J. Ellis, Lee Ponsky, Bin S. Teh, Anand Mahadevan, Alexander Muacevic, Michael Staehler, Hiroshi Onishi, Peter Wersall, Takuma Nomiya, Simon S. Lo

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

Aim: To provide a multi-institutional consensus document for stereotactic body radiotherapy of primary renal cell carcinoma. Materials & methods: Eight international institutions completed a 65-item survey covering patient selection, planning/treatment aspects and response evaluation. Results: All centers treat patients with pre-existing hypertension and solitary kidneys. Five institutions apply size constraints of 5-8 cm. The total planning target volume expansion is 3-10 mm. All institutions perform pretreatment imaging verification, while seven institutions perform some form of intrafractional monitoring. Number of fractions used are 1-12 to a total dose of 25 Gy-80 GyE. Imaging follow-up for local tumor response includes computed tomography (n = 8), PET-computed tomography (n = 1) and MRI (n = 5). Follow-up frequency is 3-6 months for the first 2 years and 3-12 months for subsequent 3 years. Conclusion: Key methods for safe implementation and practice for stereotactic body radiotherapy kidney have been identified and may aid standardization of treatment delivery.

Original language	English (US)
Pages (from-to)	637-645
Number of pages	9
Journal	Future Oncology
Volume	12
Issue number	5
DOIs	https://doi.org/10.2217/fon.16.2
State	Published - Mar 2016

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.2217/fon.16.2

Cite this

@article{3170a89066a7403abd2819c807fb6a02,

title = "Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma",

abstract = "Aim: To provide a multi-institutional consensus document for stereotactic body radiotherapy of primary renal cell carcinoma. Materials & methods: Eight international institutions completed a 65-item survey covering patient selection, planning/treatment aspects and response evaluation. Results: All centers treat patients with pre-existing hypertension and solitary kidneys. Five institutions apply size constraints of 5-8 cm. The total planning target volume expansion is 3-10 mm. All institutions perform pretreatment imaging verification, while seven institutions perform some form of intrafractional monitoring. Number of fractions used are 1-12 to a total dose of 25 Gy-80 GyE. Imaging follow-up for local tumor response includes computed tomography (n = 8), PET-computed tomography (n = 1) and MRI (n = 5). Follow-up frequency is 3-6 months for the first 2 years and 3-12 months for subsequent 3 years. Conclusion: Key methods for safe implementation and practice for stereotactic body radiotherapy kidney have been identified and may aid standardization of treatment delivery.",

author = "Shankar Siva and Ellis, {Rodney J.} and Lee Ponsky and Teh, {Bin S.} and Anand Mahadevan and Alexander Muacevic and Michael Staehler and Hiroshi Onishi and Peter Wersall and Takuma Nomiya and Lo, {Simon S.}",

note = "Publisher Copyright: {\textcopyright} 2016 Future Medicine Ltd.",

year = "2016",

month = mar,

doi = "10.2217/fon.16.2",

language = "English (US)",

volume = "12",

pages = "637--645",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma

AU - Siva, Shankar

AU - Ellis, Rodney J.

AU - Ponsky, Lee

AU - Teh, Bin S.

AU - Mahadevan, Anand

AU - Muacevic, Alexander

AU - Staehler, Michael

AU - Onishi, Hiroshi

AU - Wersall, Peter

AU - Nomiya, Takuma

AU - Lo, Simon S.

PY - 2016/3

Y1 - 2016/3

N2 - Aim: To provide a multi-institutional consensus document for stereotactic body radiotherapy of primary renal cell carcinoma. Materials & methods: Eight international institutions completed a 65-item survey covering patient selection, planning/treatment aspects and response evaluation. Results: All centers treat patients with pre-existing hypertension and solitary kidneys. Five institutions apply size constraints of 5-8 cm. The total planning target volume expansion is 3-10 mm. All institutions perform pretreatment imaging verification, while seven institutions perform some form of intrafractional monitoring. Number of fractions used are 1-12 to a total dose of 25 Gy-80 GyE. Imaging follow-up for local tumor response includes computed tomography (n = 8), PET-computed tomography (n = 1) and MRI (n = 5). Follow-up frequency is 3-6 months for the first 2 years and 3-12 months for subsequent 3 years. Conclusion: Key methods for safe implementation and practice for stereotactic body radiotherapy kidney have been identified and may aid standardization of treatment delivery.

AB - Aim: To provide a multi-institutional consensus document for stereotactic body radiotherapy of primary renal cell carcinoma. Materials & methods: Eight international institutions completed a 65-item survey covering patient selection, planning/treatment aspects and response evaluation. Results: All centers treat patients with pre-existing hypertension and solitary kidneys. Five institutions apply size constraints of 5-8 cm. The total planning target volume expansion is 3-10 mm. All institutions perform pretreatment imaging verification, while seven institutions perform some form of intrafractional monitoring. Number of fractions used are 1-12 to a total dose of 25 Gy-80 GyE. Imaging follow-up for local tumor response includes computed tomography (n = 8), PET-computed tomography (n = 1) and MRI (n = 5). Follow-up frequency is 3-6 months for the first 2 years and 3-12 months for subsequent 3 years. Conclusion: Key methods for safe implementation and practice for stereotactic body radiotherapy kidney have been identified and may aid standardization of treatment delivery.

UR - http://www.scopus.com/inward/record.url?scp=84959360316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959360316&partnerID=8YFLogxK

U2 - 10.2217/fon.16.2

DO - 10.2217/fon.16.2

M3 - Article

C2 - 26837701

AN - SCOPUS:84959360316

SN - 1479-6694

VL - 12

SP - 637

EP - 645

JO - Future Oncology

JF - Future Oncology

IS - 5

ER -

Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this